FRTX-10 / Fresh Tracks Therap, Carna Biosci - LARVOL DELTA

FRESH TRACKS THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) (Market Screener) - "In February 2022, we acquired exclusive, worldwide rights to research, develop, and commercialize a portfolio of novel, preclinical-stage oral Stimulator of Interferon Genes ('STING') inhibitors. STING is a well-known mediator of innate immune responses. Excessive signaling through STING is linked to numerous high unmet-need diseases, ranging from autoimmune disorders, such as systemic lupus erythematosus, to interferonopathies, which are a set of rare genetic conditions characterized by interferon overproduction and could have orphan drug potential."

Preclinical • Interferonopathies • STING-Associated Vasculopathy with Onset in Infancy

Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) - "Brickell Biotech...Research and Development Highlights...BBI-10: a covalent Stimulator of Interferon Genes (STING) inhibitor for the potential treatment of autoimmune, inflammatory, and rare genetic diseases Preclinical development activities for BBI-10, the Company’s lead STING inhibitor candidate, are underway."

Preclinical • Interferonopathies • STING-Associated Vasculopathy with Onset in Infancy